Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT ) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.

EyePoint Reports Disappointing Phase 3 Clinical Trials On August 17, 2026, EyePoint issued a press release "announc[ing] topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU™ (vorolanib intravitreal insert) for the treatment of wet age-related macular degeneration (wet AMD)." Specifically, EyePoint disclosed that DURAVYU did not meet the prespecified primary endpoint -- change in best-corrected visual acuity versus on-label aflibercept -- in the full dataset of the company's Phase 3 LUGANO trial in wet age-related macular degeneration.

EyePoint's Stock Drops Over 66% Following the news of EyePoint, Inc.'s poor clinical trial results, the company's stock price fell over 66%. Investors who purchased EyePoint, Inc. (NASDAQ: EYPT ) securities and experienced losses may have legal rights under the federal securities laws.